Hope Tribune

Graft-versus-host disease Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working

 Breaking News
  • No posts were found

Graft-versus-host disease Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working

October 12
20:29 2021
Graft-versus-host disease Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working
DelveInsight Business Research LLP
DelveInsight’s ‘Graft Versus Host Disease (GvHD) – Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the GvHD, historical and forecasted epidemiology as well as the GvHD market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

DelveInsight has launched a new report on “Graft-versus-host disease – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Graft-versus-host disease – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Graft-versus-host disease, historical and forecasted epidemiology as well as the Graft-versus-host disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Graft-versus-host disease Market Report:

  • In 2020, the seven major countries reported 24,049 allogeneic cases, with a CAGR projecting an increased number of cases by 2030. The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.

  • GvHD is categorized into two types: aGvHD and cGvHD. In the 7MM, acute GvHD cases accounted for 11,638, while chronic cases accounted for 7,854 in the year 2020, which is expected to rise during the forecast period. 

  • Germany has the highest number of GvHD cases by type (acute and chronic) among the EU-5 nations, with 2,984 cases in 2020. 

  • In 2020, the overall number of cGvHD cases by grading in the United Kingdom were  134, 209, and 159 respectively for mild, moderate, and severe cGvHD. According to the analysis, by 2030, the total number of severity-specific incident cases for the cGvHD is predicted to grow at a significant rate in the United Kingdom.

Key benefits of the report:

  1. Graft-versus-host disease market report covers a descriptive overview and comprehensive insight of the Graft-versus-host disease Epidemiology and Graft-versus-host disease  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

  2. The Graft-versus-host disease market report provides insights on the current and emerging therapies.

  3. Graft-versus-host disease market report provides a global historical and forecasted market covering drug outreach in 7MM.

  4. The Graft-versus-host disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Graft-versus-host disease market.

Got queries? Click here to know more about the Graft-versus-host disease Market Landscape.

Graft-versus-host disease Overview

Graft-versus-host disease (GvHD) is an immune condition that occurs when immune cells (T cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host’s tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem Cell Transplantation).

Graft-versus-host disease Market 

The dynamics of the Graft-versus-host disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as CSL Behring, Medac, ElsaLys Biotech, Kadmon Therapeutics, Incyte Corporation, and others during the forecasted period 2018-2030.

Learn more by requesting for sample @ Graft-versus-host disease Market Landscape 

Graft-versus-host disease Pipeline Therapies and Key Companies 

  • CSL 964 AAT (Zemaira): CSL Behring

  • Obnitix: Medac

  • Leukotac (Inolimomab): ElsaLys Biotech

  • KD025 (Belumosudil): Kadmon Therapeutics

  • Itacitinib: Incyte Corporation

Graft-versus-host disease Market Drivers 

  • Increased participation in clinical trials along with novel strategies

  • The rise in the number of cases of allogeneic stem cell transplant

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Graft-versus-host disease Patient Share (%) Overview at a Glance

5. Graft-versus-host disease Market Overview at a Glance

6. Graft-versus-host disease Disease Background and Overview

7. Graft-versus-host disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Graft-versus-host disease 

9. Graft-versus-host disease Current Treatment and Medical Practices

10. Unmet Needs

11. Graft-versus-host disease Emerging Therapies

12. Graft-versus-host disease Market Outlook

13. Country-Wise Graft-versus-host disease Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Graft-versus-host disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Graft-versus-host disease Market Outlook 2030. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/